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Abstract
Background: Nutritional vitamin D deficiency is an emerging risk factor for acute myocardial infarction (AMI) and
heart failure. The association of 25-hydroxyvitamin D levels with N-terminal pro B-type natriuretic peptide (NT-
proBNP), a robust prognostic marker for post-AMI mortality and heart failure, is unknown and could illuminate a
potential pathway for adverse outcomes among post-AMI patients with 25-hydroxyvitamin D deficiency.
Methods: In a cross-sectional analysis, we studied 238 AMI patients from 21 U.S. centers to test the association of
nutritional vitamin D (25-hydroxyvitamin D [25(OH)D]) deficiency with NT-proBNP levels. Levels of 25(OH)D levels
were categorized as normal (≥30 ng/mL), insufficient (>20 - <30 ng/mL), deficient (>10 - ≤20 ng/mL), or severely
deficient (≤10 ng/mL).
Results: Low 25(OH)D levels were found in 95.7% of AMI patients. No significant trends for higher mean baseline
log NT-proBNP levels in severely deficient (6.9 ± 1.3 pg/mL), deficient (6.9 ± 1.2 pg/mL), and insufficient (6.9 ± 0.9
pg/ml) groups were observed as compared with patients having normal (6.1 ± 1.7 pg/mL) levels, P = 0.17. Findings
were similar in the subset of patients who had follow-up NT-proBNP levels drawn at one month. In multivariate
regression modeling, after adjusting for multiple covariates, 25(OH)D was not associated with NT-proBNP.
Conclusions: Potential associations between nutritional vitamin D deficiency and prognosis in the setting of AMI
are unlikely to be mediated through NT-proBNP pathways. Future studies should examine other mechanisms, such
as inflammation and vascular calcification, by which 25(OH)D deficiency could mediate adverse outcomes post-AMI.
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Background
Deficiency in nutritional vitamin D [25-hydroxyvitamin
D, or 25(OH)D] is highly prevalent, occurring in
approximately 30%-50% of the general population [1,2]
and in an even greater percentage of hospitalized
patients [3]. In several studies, 25(OH)D deficiency has
been independently associated with both incident acute
myocardial infarction (AMI) and heart failure (HF) [4,5],
suggesting that 25(OH)D plays an important role in car-
diac function. In support of this hypothesis, several in
vitro studies have shown that calcitriol (1,25(OH)2D3),
an active form of vitamin D, regulates intracellular cal-
cium metabolism and myocardial contractility through
specific vitamin D receptors on cardiac myocytes [5-8].
Consequently, 25(OH)D deficiency has been associated
with aberrant cardiac contractility, cardiomegaly, and
increased ventricular mass due to myocardial collagen
deposition [6,7], independent of its known effects on
blood pressure [6]. In studies of experimental animals,
activation of nuclear vitamin D receptors by 1,25(OH)
2D3 suppresses the expression and secretion of atrial
natriuretic peptide (ANP) and brain natriuretic peptide
(BNP) in cardiac myocytes [9-13], while in clinical stu-
dies of nondialysis chronic kidney disease patients, indi-
viduals treated with 1,25(OH)2D3 for 12 weeks were
observed to have improved left ventricular diastolic
* Correspondence: jwetmore@kumc.edu
1Division of Nephrology and Hypertension, University of Kansas Medical
Center, Kansas City, KS, USA
Full list of author information is available at the end of the article
Wetmore et al. BMC Research Notes 2011, 4:542
http://www.biomedcentral.com/1756-0500/4/542
© 2011 Wetmore et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited.function as compared with placebo [14]. Collectively,
these findings suggest that low circulating levels of 25
(OH)D could contribute to, or potentiate, the develop-
ment of left ventricular dysfunction and HF after AMI.
In recent years, N-terminal pro B-type natriuretic pep-
tide (NT-proBNP), a prohormone of BNP released from
cardiac ventricles, has been associated with the severity
of left ventricular dilatation and dysfunction after AMI
[15,16]. In addition, NT-proBNP is a sensitive and
robust prognostic biomarker of mortality in AMI
[15,17-19], HF [20,21] and chronic hemodialysis patients
[22,23]. Moreover, NT-proBNP levels have direct clinical
implications, as they are used to guide therapeutic inter-
ventions in HF patients and lead to improved outcomes
as compared with routine clinical treatment [24].
While both 25(OH)D and NT-proBNP are known to
be associated with LV dysfunction after AMI, it is not
known whether there is a correlation between levels of
25(OH)D and NT-proBNP in this setting. In clinical stu-
dies, inverse associations between 25(OH)D levels and
NT-proANP in HF [5] and between 25(OH)D and BNP
in dialysis patients have been reported [25,26]. However,
these studies had small sample sizes and were not based
on patients living in the U.S., where better nutrition and
fortification of milk is common [27]. Given the adverse
health implications of 25(OH)D deficiency and the lack
of studies in AMI patients (a particularly high-risk
group), we sought to examine the association of 25(OH)
D deficiency with NT-proBNP levels in a multicenter
cohort of AMI patients. Discovery of an association
between circulating levels of 25(OH)D and NT-proBNP
would not only suggest a potential pathway for adverse
outcomes among post-AMI patients with 25(OH)D defi-
ciency, but could also identify a potentially novel thera-
peutic target (i.e., nutritional vitamin D
supplementation) to reduce NT-proBNP levels, in the
hopes of improving prognosis after AMI.
Methods
Study participants
The present study is a cross-sectional analysis of a long-
itudinal cohort study. Participants were drawn from the
TRIUMPH (Translational Research Investigating Under-
lying disparities in recovery from acute Myocardial
infarction: Patients’ Health status) study, a prospective
multicenter cohort study of AMI patients across 21 U.S.
centers [28]. Patients were eligible for TRIUMPH if they
were ≥ 18 years of age and had a diagnosis of AMI.
AMI was diagnosed by the presence of either a CK-MB
elevation greater than twice normal or a troponin-I ele-
vation of >0.1 mg/ml within 24 h of arrival to the hospi-
tal, accompanied by a clinical presentation suggestive of
an AMI (e.g., prolonged ischemic signs or chest pain
symptoms, at least one EKG with ST-wave elevation or
ST-wave depression in 2 or more consecutive leads, and
no alternative explanation for the presence of elevated
serum cardiac markers). Patients were excluded if they
transferred to the participating hospital from another
facility greater than 24 h after their original AMI pre-
sentation, if they refused or could not provide informed
consent, or if they were receiving hospice care. For this
study, we included the last 250 TRIUMPH patients, in
each of whom 25(OH)D levels were assessed in addition
to the standard data collected [29]. TRIUMPH complied
with the principles of the Declarations of Helsinki and
was approved by the institutional review board at the
coordinating center, Mid America Heart Institute at St.
Luke’s Hospital (Kansas City, MO). Written informed
consent was obtained from all participants.
Data collection
During index hospitalization, trained data collectors per-
formed a patient interview and detailed chart abstraction
within 24-72 h of admission. Patient data at AMI pre-
sentation, including demographic features, socioeco-
nomic status, comorbidities, severity of AMI (ST
elevation present or not), Killip class, Rose dyspnea
index, vital signs, and laboratory values were abstracted.
The Rose dyspnea score is a validated self-reported
question in AMI patients that is scored from 0-4, with
higher scores indicating worse dyspnea [30]. Regional
and seasonal data were collected, given their association
with 25(OH)D levels [31,32]. Patients were classified by
their residing states in to 5 U.S. geographic regions,
namely northeast (NE), southeast (SE), southwest (SW),
midwest (MW) and west (W). Months of April-June,
July-August and September-December were classified as
summer, fall, and early winter seasons, respectively.
Left ventricular systolic function (LVSF) was classified
as normal, mild, moderate or severe as assessed by
echocardiography, angiography or nuclear imaging and
documented in the hospital record. Finally, reperfusion
therapy (percutaneous intervention [PCI] and/or coron-
ary artery bypass surgery [CABG]) and other acute
therapies, as well as medications prescribed at hospital
discharge, were recorded. Blood samples from all con-
senting patients were sent to a core laboratory (Clinical
Reference Laboratories, Lenexa, KS, USA) for NT-
proBNP measurement (Roche Diagnostics, Indianapolis,
IN, USA) and 25(OH)D assays, as described below.
Laboratory measurements
An in vitro radioimmunoassay[33] assay (DiaSorin, Still-
water, MN, USA) was used for quantitative determina-
tion of 25(OH)D and other hydroxylated vitamin D
metabolites in human serum. The DiaSorin 25(OH)D
assay comprises a two-step procedure involving both a
rapid extraction of 25(OH)D and other hydroxylated
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along with a 25(OH)D-specific antibody and tracer, and
phase separation with a second antibody-precipitating
complex. The total (intra-and inter-assay) precision of
the assay has a coefficient of variation (CV) of 9.4% and
11% for control values of 8.6 ng/mL and 49.0 ng/ml,
respectively.
For measurement of circulating NT-proBNP levels, the
Roche electro-chemiluminescence immunoassay for the
in vitro quantization was used (ECLIA Roche diagnos-
tics, Mannheim, Germany). The precision of this assay
was represented by a CV of 3.2% and 2.3% for control
values of 175 pg/mL and 4962 pg/mL, respectively.
Blood samples for NT-proBNP were drawn immediately
prior to hospital discharge. The mean time of the NT-
proBNP blood draw was 3.5 ± 4 days after enrollment.
Glomerular filtration rate (eGFR) was estimated using
the four variable Modification of Diet in Renal Disease
(MDRD) study equation [34].
Statistical analysis
Participants were classified into clinically-relevant cate-
gories on the basis of 25(OH)D levels. Patients with
levels ≥30 ng/mL were classified as normal, while levels
>20 ng/mL and <30 ng/ml were considered insufficient,
levels of >10 to ≤20 ng/ml were deficient, and levels ≤10
ng/mL were severely deficient. Median NT-proBNP
levels were compared using the non-parametric Kruskal-
Wallis test, due to the positively-skewed distribution of
NT-proBNP. Log NT-proBNP and quartiles of NT-
proBNP were compared across the four 25(OH)D strata
using ANOVA and chi-square tests, respectively, both at
baseline and, in a complementary analysis, in the sub-
group of patients who had 1-month levels of NT-
proBNP levels drawn. To confirm previously-reported
relationships, log NT-proBNP and category of LVSF was
analyzed with the linear trend test. Spearman rank cor-
relation was obtained between NT-proBNP and 25(OH)
D levels. Multivariable linear regression analysis to
determine the association of 25(OH)D levels with log
NT-proBNP was performed, adjusting for relevant cov-
ariates and confounders. The presence of a potential
interaction between NT-proBNP levels and type of AMI
(i.e., ST-elevation versus non-ST-elevation) was formally
tested using the likelihood ratio test. A P-value of <0.05
was considered statistically significant. All analyses were
conducted using SAS v9.1 software (Cary, NC, U.S.).
Results
Of the 238 enrolled patients on whom sufficient data
was available, the median 25(OH)D concentration was
16 ng/mL (interquartile range [IQR], 12-21 ng/mL). As
noted previously [29], classification of 25(OH)D levels
into more clinically-interpretable ranges showed 40
(16.8%) to be severely deficient, 138 (57.9%) to be defi-
cient, and 50 (21.0%) to be insufficient. Only 4.2% of
participants in the study had normal 25(OH)D levels,
with none of the African-American participants having
normal levels.
Characteristics of participants across 25(OH)D groups
are shown in Table 1. No statistically-significant differ-
ences by age or gender were noted across 25(OH)D
groups. Deficiency in 25(OH)D was associated with
non-Caucasian (i.e., African-American) race, lower
socioeconomic status indicators, a history of recent
smoking, and lower levels of physical activity. No differ-
ence in those with or without 25(OH)D deficiency were
observed for diabetes, hypertension, chronic kidney dis-
ease, chronic HF, left ventricular hypertrophy on admis-
sion electrocardiogram, Kullip class, Rose dyspnea score,
or the type of AMI (STEMI vs. NSTEMI). During the
study period, no statistically-significant regional varia-
tions were observed in patients’ enrollment across 25
(OH)D groups, although there was a trend towards sea-
sonal variation in 25(OH)D levels (P = 0.064), with the
winter months being associated with the lowest levels.
Estimated glomerular filtration rates did not differ. In
terms of laboratory values, lower serum calcium and
higher parathyroid hormone (PTH) levels were signifi-
cantly associated with 25(OH)D deficiency (P = 0.03 and
P = 0.004, respectively), as would be expected. Likewise,
the use of omega-3 supplements was significantly
greater higher in patients with normal 25(OH)D levels
compared to those who had insufficient, deficient, or
severely-deficient levels (P = 0.002).
Continuous data shown as mean ± 1 standard devia-
tion. 25(OH)D, 25-hydroxyvitamin D; BMI, body mass
index; MI, myocardial infarction; CKD, chronic kidney
disease; LVH, left ventricular hypertrophy; ECG, elec-
trocardiogram; MI, myocardial infarction; STEMI, ST-
segment elevation myocardial infarction; LV, left ven-
tricular; HDL, high density lipoprotein; LDL, low den-
sity lipoprotein; PTH, parathyroid hormone; hs-CRP,
high sensitivity C-reactive protein; eGFR, estimated
glomerular filtration rate; ACEI, angiotensin convert-
ing enzyme inhibitor; ARB, angiotensin receptor
blocker.
To confirm the existence of the expected association
of LVSF with NT-proBNP levels, we examined this rela-
tionship in terms of both absolute and log-transformed
baseline NT-proBNP levels. There was a significant
graded association: individuals with normal LVSF had a
mean baseline NT-proBNP level of 1296 pg/mL; those
with mildly-decreased LVSF, 1833 pg/mL; those with
moderately-decreased LVSF, 4461 pg/mL; and those
with severely-decreased LVSF, 5776 pg/mL (P < 0.001 in
the cases of both log-transformed and untransformed
NT-proBNP levels).
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25(OH)D group, ng/mL
0-10 >10-≤20 >20-<30 ≥30
Characteristic (n = 40) (n = 138) (n = 50) (n = 10) P-value
Demographics
Age (yr) 55.0 ± 11.2 57.8 ± 11.8 58.8 ± 10.2 62.4 ± 11.3 0.21
Male, n (%) 26(65.0) 104(75.4) 38 (76.0) 8 (80.0) 0.57
Caucasian, n (%) 23 (57.5) 103 (74.6) 41 (82.0) 10 (100.0) 0.012
BMI (kg/m
2) 32.1 ± 5.6 30.9 ± 6.9 29.5 ± 5.6 26.5 ± 4.6 0.066
Socio-economic status
Low social support, n (%) 11 (27.5) 20 (14.9) 3 (6.0) 0 (0) 0.023
No health insurance, n (%) 14 (35.0) 28 (20.9) 5 (10.4) 1 (10.0) 0.036
Lifestyle
Smoked within 1 month, n (%) 24 (60.0) 49 (35.5) 15 (30.0) 0(0) <0.001
Leisure time activity, n (%) 0.047
Mainly sedentary 20 (50.0) 56 (40.9) 19 (38.0) 1 (10.0)
Mild exercise 13 (32.5) 49 (35.8) 11 (22.0) 3 (30.0)
Moderate exercise 6 (15.0) 27 (19.7) 17 (34.0) 4 (40.0)
Strenuous exercise 1 (2.5) 5 (3.6) 3 (6.0) 2 (20.0)
Geographical region, n (%) 0.79
Midwest 18 (56.3) 53 (45.3) 15 (34.1) 5 (62.5)
Northeast 3 (9.4) 15 (12.8) 5 (11.4) 0 (0)
Southeast 5 (15.6) 23 (19.7) 9 (20.5) 1 (12.5)
Southwest 4 (12.5) 22 (18.8) 12 (27.3) 2 (25.0)
West 2 (6.3) 4 (3.4) 3 (6.8) 0 (0)
Season, n (%) 0.064
Apr-Jun 1 (2.5) 1 (0.7) 0 (0) 0 (0)
Jul-Sep 10 (25.0) 56 (40.6) 24 (48.0) 7 (70.0)
Oct-Dec 29 (72.5) 81 (58.7) 26 (52.0) 3 (30.0)
Comorbidities, n (%)
Diabetes 13 (32.5) 41 (29.7) 8 (16.0) 2 (20.0) 0.21
Hypertension 26 (65.0) 89 (64.5) 33 (66.0) 6 (60.0) 0.99
Prior MI 2 (5.0) 36 (26.1) 9 (18.0) 2 (20.0) 0.019
CKD 5 (12.5) 4 (2.9) 2 (4.0) 1 (10.0) 0.06
Chronic heart failure 3 (7.5) 6 (4.3) 1 (2.0) 1 (10.0) 0.38
LVH on admission ECG, n (%) 7 (17.9) 9 (6.7) 4 (8.2) 0 (0) 0.18
Killip class on arrival, n (%) 0.35
I 36 (94.7) 128 (94.8) 43 (86.0) 9 (90.0)
II 2 (5.3) 4 (3.0) 5 (10.0) 1 (10.0)
III 0 (0) 2 (1.5) 2 (4.0) 0 (0)
IV 0 (0) 1 (0.7) 0 (0) 0 (0)
Rose dyspnea score 1.0 ± 0.9 0.9 ± 0.9 0.8 ± 0.8 0.6 ± 1.0 0.43
Final MI diagnosis, n (%) 0.36
STEMI 15 (37.5) 64 (46.4) 23 (46.0) 2 (20.0)
Non-STEMI 25 (62.5) 74 (53.6) 27 (54.0) 8 (80.0)
LV systolic function, n (%) 0.54
Normal 24 (61.5) 88 (63.8) 36 (72.0) 6 (60.0)
Mild 8 (20.5) 24 (17.4) 10 (20.0) 1 (10.0)
Moderate 4 (10.3) 16(11.6) 4 (8.0) 1 (10.0)
Severe 3 (7.7) 10 (7.2) 0 (0) 2 (20.0)
Laboratory values
Troponin I (ng/ml) 1.4 ±1.9 1.7 ± 1.8 1.6 ± 1.7 0.7 ± 1.2 0.3
Total Cholesterol (mg/dl) 150.6 ± 47 157.3 ± 29 150.5 ± 29 189.7 ± 47 0.011
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line log NT-proBNP levels are shown in Figure 1 and-
Table 2. No statistically-significant correlation between
25(OH)D and baseline log NT-proBNP levels was
observed (rho = - 0.0025, P = 0.97; Figure 1). No signifi-
cant trends for higher mean log NT-proBNP levels in
severely deficient (6.9 ± 1.3 pg/mL), deficient (6.9 ± 1.2
pg/mL) and insufficient (6.9 ± 0.9 pg/mL) groups were
observed as compared with patients having normal (6.1
± 1.7 pg/ml) levels, (P =0 . 1 7 ;T a b l e2 ) .I nas e n s i t i v i t y
analysis, when patients were stratified into quartiles of
NT-proBNP, there was also no statistically significant
association between 25(OH)D levels and category of
NT-proBNP levels (P = 0.58, Table 2).
Continuous data shown as mean ± 1 standard devia-
tion. 25(OH)D, 25-hydroxyvitamin D; NT-proBNP, N
terminal pro brain natriuretic peptide
Because NT-proBNP levels can vary in the setting of
AMI, we analyzed the subset (n = 66) of individuals who
had NT-proBNP levels drawn one month after discharge.
Again, there was no association between initial 25(OH)D
levels and 1-month NT-proBNP levels (P = 0.82)
In the multivariable linear regression model (shown in
Table 3), after adjustment for demographic (age, race,
Figure 1 Spearman correlation between levels of 25(OH)D and NT-proBNP.
Table 1 Baseline characteristics of study participants, by 25(OH)D group (Continued)
HDL(mg/dl) 37.9 ± 10.6 38.4 ± 8.7 40.6 ± 10.7 43.1 ± 25.2 0.36
LDL (mg/dl) 92.2 ± 36.7 97.4 ± 25 90.4 ± 25.7 119.2 ± 42.8 0.032
Triglycerides(mg/dl) 153.2 ± 74 185.6 ± 145 143.6 ± 79 195.4 ± 169 0.17
Calcium (mg/dl) 8.9 ± 0.6 8.8 ± 0.6 9.0 ± 0.4 9.3 ± 0.6 0.038
Intact PTH (pg/ml) 59.8 ± 67.7 40.1 ± 28.1 32.8 ± 15.3 32.0 ± 26.5 0.004
Phosphate (mg/dl) 3.6 ± 0.7 3.5 ± 0.8 3.5 ± 0.7 3.7 ± 0.9 0.69
hs-CRP (mg/l) 5.2 ± 5.6 3.8 ± 5.3 3.8 ± 4.5 0.9 ± 0.8 0.12
eGFR, mL/min/1.73 m
2 84.7 ± 28.1 88.3 ± 27.3 80.3 ± 18.9 80.1 ± 18.8 0.25
Medications
ACEI/ARB, n (%) 11 (27.5) 39 (28.3) 18 (36.0) 1 (10.0) 0.43
Diuretic, n (%) 9 (22.5) 31 (22.5) 15 (30.0) 10(10.0) 0.58
Omega-3 supplements, n (%) 3 (7.5) 31 (22.5) 18 (36.0) 5 (50.0) 0.002
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support, medical insurance), lifestyle (smoking status),
seasonal, comorbidity (diabetes and history of prior MI),
treatment (in-hospital percutaneous coronary interven-
tion [PCI] or coronary artery bypass graft [CABG]),
laboratory (high sensitivity C-reactive protein [hs-CRP],
estimated GFR) and medication (omega-3 supplement
use) factors, 25(OH)D levels were not significantly asso-
ciated with log NT-proBNP levels (P =0 . 1 2 ) .H o w e v e r ,
NT-proBNP levels were independently and strongly
associated with age, race, hs-CRP, and eGFR.
BMI, body mass index; MI, myocardial infarction; PCI,
percutaneous coronary intervention; CABG, coronary
artery bypass graft; hs-CRP, high sensitivity C-reactive
protein; eGFR, estimated glomerular filtration rate; 25
(OH)D, 25-hydroxyvitamin D
Finally, we considered the theoretical possibility that
our results might be affected by type of AMI (ST-eleva-
tion versus non-ST-elevation), so we formally tested for
an interaction between type of AMI and NT-proBNP
levels; none was found (P = 0.2)
Conclusions
In this cross-sectional observational study, we found no
evidence of an association between levels of 25(OH)D
and NT-proBNP upon discharge, nor was there evidence
of an association at one month in the subset of tested
patients. To our knowledge, this is the first study to
examine levels 25(OH)D and NT-proBNP in an AMI
population. Thus, while both 25(OH)D and NT-proBNP
levels are associated with cardiovascular disease and
heart failure, they appear to impact prognosis through
different mechanisms in the setting of AMI. However,
we extend our previous findings [29] in this AMI cohort
by showing that 25(OH)D levels are associated with
smoking, lower degrees of physical activity, and lesser
use of omega-3 supplements in bivariate analysis, con-
sistent with previous reports [1,31,35]. That low social
support and lack of medical insurance were associated
i nag r a d e dm a n n e ra c r o s sf i n ec a t e g o r i e so f2 5 ( O H ) D
level suggest that these factors, both of which are asso-
ciated with higher morbidity and mortality after MI
[36-38], should be investigated in more depth in future.
Additionally, although our data do not support an inde-
pendent association between 25(OH)D deficiency and a
biomarker of left ventricular dysfunction, namely NT-
proBNP, in the setting of AMI, the high prevalence of
25(OH)D deficiency, which has been associated with
incident MI [4] in prior observational studies, is an
important area of future investigation. It would be criti-
cal to examine, for instance, whether rectifying low
nutritional vitamin D levels in post-AMI patients is
associated with an improvement in long-term outcomes.
Our findings extend and confirm insights provided by
Pilz et al., who studied patients with established CAD
referred to coronary angiography [39]. While these
investigators found that 25(OH)D deficiency was signifi-
cantly associated with higher New York Heart Associa-
tion functional HF classes in unadjusted analysis, this
association was no longer significant after adjustment
Table 3 Multivariable regression analysis showing
association of factors with NT-proBNP levels
Covariate b coefficient P-value
Age, per 10-yr increment 0.27 0.0006
Caucasian race 0.365 0.04
Male sex -0.165 0.31
BMI, per 5 units kg/m
2 increment -0.105 0.08
Lack of social support -0.209 0.31
No health insurance 0.26 0.19
Smoked within 1 month 0.03 0.85
Season, Nov-Feb vs. Mar-Oct 0.184 0.22
History of diabetes -0.02 0.9
History of prior MI 0.262 0.12
In-hospital PCI 0.202 0.23
In-hospital CABG -0.147 0.56
hs-CRP, per 5 units mg/L increment 0.449 <0.0001
eGFR, per 5 units mL/min increment -0.04 0.008
Omega-3 supplements -0.224 0.18
25(OH)D, per 10 ng/mL increment -0.203 0.12
Table 2 Association of 25(OH)D levels with NT-proBNP levels
25(OH)D level, ng/mL
0-10 >10-≤20 >20-<30 ≥30
Characteristic (n = 40) (n = 138) (n = 50) (n = 10) P-value
Median NT-proBNP (pg/mL) 1094.5 897.5 1065.5 757.5 0.46
Mean log NT-pro BNP 6.9 ± 1.3 6.9 ± 1.2 6.9 ± 0.9 6.1 ± 1.7 0.17
NT-pro BNP (pg/mL), n (%) 0.58
Quartile 1 (5 to <488), 58 (24.3) 11 (27.5) 34 (24.6) 10 (20.0) 3 (30.0)
Quartile 2 (488 to <924.5), 61(25.6) 8 (20.0) 38 (27.5) 13 (26.0) 2 (20.0)
Quartile 3 (924.5 to <1882), 59 (24.7) 9 (22.5) 31 (22.5) 14 (28.0) 5 (50.0)
Quartile 4 (1882 to 31230), 60 (25.2) 12 (30.0) 35 (25.4) 13 (26.0) 0(0)
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somewhat dissimilar from prior observations in chronic
hemodialysis patients, where lower 25(OH)D levels were
found to be associated with significantly higher log BNP
levels [25]. NT-proBNP is a more stable form of BNP
and correlates well with BNP levels in HF patients [40].
Similar reports in chronic HF patients have also sug-
gested an inverse, nonlinear association between 25(OH)
D and NT-proANP levels [5], although a clinical trial of
nutritional vitamin D supplementation failed to alter
patients’ NT-proBNP levels [41].
More recently, a large cohort of patients referred to
coronary angiography in the LUdgwigshafen RIsk and
Cardiovascular Health (LURI C )s t u d ys u g g e s t e dt h a t2 5
(OH)D levels remained independently associated with
NT-proBNP levels in a multivariable model (b = -0.180,
P<0.001) [39]. It is unknown whether the discrepancy in
our findings and those of previous studies is due to
unmeasured confounding in prior reports, or to the
impact of acute myocardial injury (present in all partici-
pants of our study) on NT-proBNP levels [42,43]. Acute
effects of MI could overwhelm or mask the basal asso-
ciation of 25(OH)D with NT-proBNP found in a more
stable condition (such as that of the participants of the
LURIC study[39]), given that NT-proBNP levels are
influenced by acute ischemia [33] and can change over
time [44]. We did, however, specifically examine the
association of 25(OH)D levels and 1-month NT-proBNP
levels in a subset of patients and found results similar to
our primary analysis of baseline (hospital discharge)
NT-proBNP levels, suggesting that volatility in NT-
proBNP levels in the setting of AMI may not be respon-
sible for our findings.
The results of our study should be interpreted in the
context of some limitations. Our sample size was small,
and therefore was underpowered for some analyses.
However, our study of 238 patients did have 80% power
to observe an unadjusted correlation of 0.18 between 25
(OH)D and NT-proBNP levels (a level comparable to
that of the LURIC study[39]). Nevertheless, we cannot
of course be entirely certain of our findings, so more
work in this regard must be performed. Additionally,
there were very few patients (n = 10) who had normal
25(OH)D levels, and if there is a non-linear association
between outcome and normal 25(OH)D levels, we may
have been underpowered to detect this. It is also possi-
ble that the association between the biomarkers we
tested might have been stronger at a time of clinical sta-
bility or, conversely, at the time of acute presentation,
since our samples for both 25(OH)D and NT-proBNP
were taken prior to discharge; however the prognostic
importance of NT-proBNP at the time of MI has consis-
tently been shown to be strong [18,19], and we
performed the 1-month analysis to increase confidence
in our findings.
In conclusion, the mechanism by which nutritional
vitamin D deficiency mediates outcomes in AMI
patients does not appear to be through its effects on, or
a relationship with, NT-proBNP. Future studies should
better clarify the clinical mechanism by which 25(OH)D
deficiency is associated with outcomes in AMI patients.
Potential candidates might include more long-term pro-
cesses such as inflammation and vascular calcification.
While we did not observe an association between levels
of 25(OH)D and NT-proBNP, we did find a remarkably
high frequency of 25(OH)D deficiency among AMI
patients, consistent with other reports of hospitalized
patients [3]. Hospitalization for AMI offers clinicians an
opportunity to not only identify modifiable risk factors
and to optimize medications for secondary prevention,
but also to address other comorbidities, such as 25(OH)
D deficiency. Given that nutritional vitamin D is readily
available, inexpensive, and has a good safety profile,
future studies should investigate whether addressing 25
(OH)D deficiency might improve outcomes in AMI
patients, regardless of the mechanism of its known asso-
ciation with post-AMI risk.
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